1. Oncoforum Urology: Prostate Cancer 2008 at a Glance
Nicolas Mottet 
European Urology Supplements 
Volume 8, Issue 12, Pages (December 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
The risk of nodal disease in men with ≥50% or <50% of the biopsy cores being positive for prostate cancer [4].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Use of prostate-specific antigen (PSA) progression to predict overall survival in patients with metastatic prostate cancer treated with continuous androgen deprivation therapy (phase 3 S9346 trial) and docetaxel or mitoxantrone plus prednisone (phase 3 S9916 trial) [5].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

4. Fig. 3
Benefit of adjuvant radiotherapy to radical prostatectomy among men with pT3 prostate cancer enrolled in the Southwest Oncology Group (SWOG) 8794 trial [15].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions